Cytomegalovirus prophylaxis/pre-emptive therapy | ||||||||
Study | AE | Breakthrough infection | Graft loss | Death | Patient decision | Physician/investigator decision | Other | Total number subjects |
Humar et al, 201015 | 27 (8%) | 51 (16%) | 11 (3%) | 14 (4%) | 320 | |||
Halim et al, 201631 | 2 (1%) | 1 (0.5%) | 201 | |||||
Reischig et al, 201235 | 10 (14%) | 2 (3%) | 70 | |||||
Reischig et al, 201536 1 | 13 (11%) | 4 (3%) | 3 (2.5%) | 119 | ||||
Padulles et al, 201625 | 1 (2%) | 53 | ||||||
Palmer et al, 201027 | 17 (12.5%) | 7 (5%) | 3 (2%) | 15 (11%) | 3 (2%) | 136 | ||
Boeckh et al, 201529 | 44 (24%) | 35 (19%) | 20 (11%) | 184 | ||||
Kim et al, 201030 | 1 (1.5%) | 2 (3%) | 68 | |||||
Montejo et al, 201039 | 3 (9%) | 34 | ||||||
Perrottet et al, 200941 | 3 (viremia) | 65 | ||||||
McGillicuddy et al, 201042 | 3 (2%) | 1 (1%) (2) | 130 | |||||
Park et al, 201249 3 | 8 (8%) | 6 (6%) | 37 (38%) | 97 | ||||
Invasive fungal infection prophylaxis | ||||||||
Winston et al, 201417
4
Fluconazole | 2 (2%) | 1 (1%) | 2 (2%) | 100 (fluconazole) 200 (total) | ||||
Chaftari et al, 201248
Posaconazole | 8 (38%) | 21 (posaconazole) 40 (total) | ||||||
Huang et al, 201219
Itraconazole | 29 (20%) | 12 (8%) | 1 (1%) | 4 (3%) | 147 (itraconazole) 228 (total) | |||
Park et al, 201649
Fluconazole | 2 (2%) | 3 (3%) | 3 (3%) | 89 (fluconazole) 250 (total) | ||||
Mitsani et al, 201243 | 25 (27%) | 93 | ||||||
Cordonnier et al, 201044 | 2 (4%) | 3* (7%) | 11* (2%) | 45 | ||||
NI in the following trials (timepoints not specified) | ||||||||
Nanmoku et al, 201840 | 100 | |||||||
Chawla et al, 201128 | 37 | |||||||
Witzke et al, 201233 | 296 | |||||||
Perrella et al, 201247 | 43 | |||||||
All patients completed treatment protocol in the following trials | ||||||||
Togashi et al, 201138 | 22 | |||||||
Takenaka et al, 201245 | 20 |
1. One patient moved to another country.
2. No information on breakthrough infections during prophylaxis.
3. 12 patients had dosage reductions.
4. 36 patients were preliminarily stopped due to discharge from hospital.
*Time-point not confirmed.
AE, adverse event; CMV, cytomegalovirus; IFI, invasive fungal infection; NI, no information (not reported).